Cargando…
Prevention of bone metastases and management of bone health in early breast cancer
Treatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for these women. Several recent studies demonstrated that the anticancer activity of...
Autores principales: | Gnant, Michael, Hadji, Peyman |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046430/ https://www.ncbi.nlm.nih.gov/pubmed/21172067 http://dx.doi.org/10.1186/bcr2768 |
Ejemplares similares
-
The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
por: Hadji, P., et al.
Publicado: (2012) -
Prevention and Treatment of Bone Metastases in Breast Cancer
por: Carla, Ripamonti, et al.
Publicado: (2013) -
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer
por: Waqas, Komal, et al.
Publicado: (2021) -
The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
por: Hadji, Peyman, et al.
Publicado: (2012) -
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)